Vanda's quarterly revenue rose 24.1% year over year to $69.8M in 2026Q3, and gross margins held near 90-95% across all ten reported quarters, suggesting the core product economics remain strong.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | -$0.37+45.7% vs -$0.68 | $70M+0.9% vs $69M |
Q3 2026 Aug 5, 2026 | -$1.04-78.5% vs -$0.58 | $51M-18.4% vs $62M |
Q2 2026 May 6, 2026 | -$0.82-54.7% vs -$0.53 | $52M-5.9% vs $55M |
Q1 2026 Feb 11, 2026 | -$2.39-9.6% vs -$2.18 | $57M-3.5% vs $59M |
WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in November 2026: The 8th Annual Wolfe Research Healthcare Conference in New York City on Tuesday, November 10, 2026. The Stifel 2026 Healthcare Conference in New York City on Wednesday, November 11, 2026.
Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals NASDAQ: VNDA reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to specialty-pharmacy purchasing and shipment timing. The company also said operating expenses declined 18% from the second quarter as certain late-stage development and launch-preparation activities concluded.
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.38 per share a year ago.
Benchmark VNDA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vanda Pharmaceuticals Inc. (VNDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.82 | $229.72M | -0.84 | 8.72% | -119.87% | -106.94% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $36.43 | $1.43B | 39.43 | 3.63% | 5.08% | 5.53% | — |
Vanda Pharmaceuticals Inc. (VNDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vanda Pharmaceuticals Inc. (VNDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Aug 5, 2026·SEC
Jun 5, 2026·SEC
Get notified when VNDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vanda Pharmaceuticals Inc. (VNDA) stock FAQ — growth, dividends, profitability & financials explained
Vanda Pharmaceuticals Inc. (VNDA) reported $229.3M in revenue over the trailing twelve months. Revenue was $216.1M in fiscal year 2025. That is 635877% more than the $0.0M of fiscal year 2004.
Vanda Pharmaceuticals Inc. (VNDA) grew revenue by 8.1% over the trailing twelve months, compared with the twelve months before.
No. Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $274.8M over the trailing twelve months.
Vanda Pharmaceuticals Inc. (VNDA) had a return on equity (ROE) of -106.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Vanda Pharmaceuticals Inc. (VNDA) had negative free cash flow of $190.4M over the trailing twelve months.
